leisure time -WSS

leisure time

author：hotspot 2025-10-02 19:20:34 - browse：53

Cambridge: Biogen — Ruby Wallau for STAT

A plan to use new genetic techniques to treat non-genetic forms of ALS failed in an early study, Ionis and Biogen announced Thursday. The companies said they would discontinue the program.

In the randomized, 99-person trial, the companies tested a drug designed to silence a gene called ATXN2. Over the last decade, numerous drugs have been built to silence genes in ALS patients, but most of them have, fittingly, focused on rare genetic forms of ALS, where neurons die largely because of the work of a single mutated stretch of DNA.

This approach has led to an approved drug for one very small subset of ALS cases, driven by the gene SOD1, and drugs for other genes are in trials. But only perhaps 10% — or at most 20% — of ALS cases are genetic. The hope, based on some genetic data and promising mice experiments, was that lowering ATXN2 would help any patient who develops ALS.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Innovation in antibiotics is ailing. 'Brain drain' may kill it

hotspot

WSS

At ASCO, AstraZeneca reports strong data for breast cancer drug

The Pandemic Treaty must support building strong health systems

BMI, flaws aside, is found to be useful estimate of body fat in youth

Innovation in antibiotics is ailing. 'Brain drain' may kill it

WHO calls for emergency meeting on new China virus, as cases spread

Medicare to cover more brain scans for Alzheimer’s patients

entertainment

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

After affirmative action ruling, medical educators look to 'holistic review'

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

In age of alternative facts, a scholarly course on calling out crap

Woman returns to dialysis after doctors remove transplanted pig kidney

Medical records are filled with copy

FDA's Pazdur wants cancer trials to range beyond China alone

Medical records are filled with copy

FDA approves RSV monoclonal antibody for infants, toddlers

Wildfire smoke exposes gaps in outdoor worker protections

Google and Epic fight stronger regulation of AI in health care

knowledge

Ionis drug prevents swelling attacks due to hereditary angioedema

Why hospitals are withdrawing from US News rankings

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

At ASCO, AstraZeneca reports strong data for breast cancer drug

Change Healthcare can notify patients about the breach, HHS says

entertainment

hotspot

knowledge

focus